About Katharina
Dr Katharina (Nina) Kreymborg is an experienced drug discovery scientist. She has been a member of the Cancer Research Horizons Therapeutic Innovation Board since 2024.
Nina's professional passion is turning exciting scientific ideas and novel concepts into actual drugs. She has held roles across the life sciences and venture ecosystems.
Nina trained as a cancer immunotherapist in Jim Allison’s lab at Memorial Sloan Kettering Cancer Center and subsequently joined pharma research and early clinical development at Roche. At Roche, and later at Morphosys, she led and supported multiple projects at different stages between target assessment and early clinical development, including targeted cytokines, T-cell engagers, checkpoint inhibitors and myeloid activators.
Most recently, Nina has acted as an investor and company builder, identifying promising therapeutic concepts and building biotech start-up companies from the ground at Versant Ventures and now at Curie.Bio. In her current role, she works closely with founders to transform exciting scientific ideas into novel therapeutics for patients’ benefit.